Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report

Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qizheng, Zhang, Xia, Fan, Buqun, Yang, Yudie, Cui, Xiaonan, Zhang, Jie, Jiang, Kaiteng, Zhang, Chunxia, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/
https://www.ncbi.nlm.nih.gov/pubmed/36531025
http://dx.doi.org/10.3389/fonc.2022.978005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/
https://www.ncbi.nlm.nih.gov/pubmed/36531025
http://dx.doi.org/10.3389/fonc.2022.978005

Ejemplares similares